Search
for
Sort by
Research 271–300 of 529
- Comparative efficacy of oral Janus kinase inhibitors and biologics in adult alopecia areata: A systematic review and Bayesian network meta‐analysis
- Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO‐LT phase 3, open‐label study
- Application of Baricitinib in Dermatology
- Evaluation of the level of serum Interleukins (IL-2, IL-4, IL-15 andIL-17) and its relationship with disease severity in patients with alopecia areata
- Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the ALLEGRO clinical development programme
- Induction of T cell exhaustion by JAK1/3 inhibition in the treatment of alopecia areata
- Hair regrowth in alopecia areata and re‐pigmentation in vitiligo in response to treatment: Commonalities and differences
- Efficacy and safety of tofacitinib therapy in Asian patients with severe alopecia areata
- Off-Label Uses of Abrocitinib: Review of Emerging Therapeutic Applications beyond Atopic Dermatitis
- JAK 1-3 inhibitors and TYK-2 inhibitors in dermatology: Practical pearls for the primary care physician
- Alopecia Areata: Case report and review of pathophysiology and treatment with Jak inhibitors
- Case report: Psoriasiform eczema with immune-mediated comorbidities treated with upadacitinib
- A phase 2a study investigating the effects of ritlecitinib on brainstem auditory evoked potentials and intraepidermal nerve fiber histology in adults with alopecia areata
- Patient-reported outcome improvements following scalp hair regrowth among patients with Alopecia Areata: analysis of the ALLEGRO-2b/3 trial
- Post-marketing safety signals of four JAK inhibitors for alopecia areata: an indication-restricted FAERS pharmacovigilance study
- Janus kinase inhibitors for alopecia areata: A narrative review
- Population exposure–response analysis of the effect of ritlecitinib on eyebrow assessment and eyelash assessment in patients with alopecia areata
- Interleukin-15 is a hair follicle immune privilege guardian
- Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions
- Use of Jak Inhibitors in the Treatment of Alopecia Areata
- Pharmacological activities of Abrus precatorius Linn.: A comprehensive review of its ethnomedicinal uses and phytochemical profile.
- Pharmacological activities of Abrus precatorius Linn.: A comprehensive review of its ethnomedicinal uses and phytochemical profile.
- Use of oral Janus kinase inhibitors for the treatment of severe alopecia areata: narrative review and real-world experience
- Network pharmacology, molecular docking, and dynamics reveal the mechanisms of Hejie Shengfa Decoction against alopecia areata
- JAK-Inhibitors Beyond the Label: Emerging Applications in Dermatology
- Approach to Managing Recalcitrant Alopecia Areata with Combination Therapy: A Series of Five Cases in Black Pediatric Patients
- 054 Deep Analysis of CD4+ Trm Cells in Normal and Atopic Dermatitis Human Skin
- “<i>Nomen Omen</i>: The Myth of God Janus”
- INIBIDORES DA JANUS QUINASE PARA O TRATAMENTO DA ALOPECIA AREATA
- Etrasimod for alopecia areata: The scenario for a less extensive and moderate form